AstraZeneca announced a $2 billion investment to expand its biologics manufacturing footprint in Maryland, including a major expansion in Frederick and a new clinical-supply facility in Gaithersburg. The company said the program will nearly double commercial biologics capacity, bring rare-disease production onshore for the first time, and create or support about 2,600 jobs across both sites. AstraZeneca emphasized that the facilities will leverage AI, automation, and data analytics and meet high environmental standards; the sites are expected to be operational in 2029. CEO Pascal Soriot framed the move as strengthening U.S. supply‑chain resilience and patient access. The investment follows AstraZeneca’s broader $50 billion commitment and underscores a trend of large pharmas onshoring complex biologics capacity amid geopolitical and supply‑security concerns.